Estimating the eligible population for amyloid-targeting monoclonal antibody therapy in memory clinics: Application to lecanemab in France. (PubMed, J Prev Alzheimers Dis) - Oct 15, 2026 - "Overall, 9.7% (95%CI: 8.6-10.8) of patients consulting memory clinics were estimated to be eligible for lecanemab, representing approximately 18,200 individuals nationally (annual average, 2022-2024). These results inform healthcare planning for disease-modifying therapy implementation in France and comparable countries."
Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia
|
|
; Carole Dufouil; Geneviève Chêne; Leslie Grasset; Lisa Le Scouarnec; Vincent Bouteloup; Vincent Planche
|